Accelrys Unveils Post-Symyx-Merger Business Strategy Amid 42 Percent Rise in Q4 Revenues | GenomeWeb

By Uduak Grace Thomas

Accelrys said this week that its fourth quarter revenues rose 42 percent and that it has completed its integration activities with Symyx "on schedule" and within its planned budget.

During a conference call to discuss its Q4 results, CEO Max Carnecchia said that in 2011, Accelrys plans to focus on "establishing a baseline of operations for the business, optimizing our processes, and creating a foundation from which to grow and build in 2012."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.